XERIS BIOPHARMA HOLDINGS, INC. APIC, Share-based Payment Arrangement, Recognition and Exercise
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of $580.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2026-06-30 was $580.00K, a 49.65% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2026-03-31 was $847.00K, a 82.92% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2025-09-30 was $5.18M.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2025-06-30 was $1.15M.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2025 was $11.58M, a 2267.69% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2024 was $489.00K, a 1428.13% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2023 was $32.00K, a 300.00% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2022 was $8.00K, a 95.98% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 12 month |
|---|---|---|---|---|
| 2026-06-30 | $580.00K 10-Q · filed 2026-08-06 | $1.43M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $847.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $11.58M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $5.18M 10-Q · filed 2025-11-06 | $6.33M derived: sum of 2 quarters · filed 2026-08-06 | $11.29M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.15M 10-Q · filed 2026-08-06 | $6.11M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $4.96M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $489.00K 10-K · filed 2026-03-02 | |||
| 2024-09-30 | -$15.74M 10-Q · filed 2024-11-08 | |||
| 2024-03-31 | $459.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $32.00K 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$12.19M 10-Q · filed 2024-11-08 | -$12.16M derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $32.00K 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $8.00K 10-K · filed 2025-03-06 | |||
| 2022-09-30 | -$21.83M 10-Q · filed 2023-11-09 | -$21.83M derived: sum of 2 quarters · filed 2023-11-09 | -$21.83M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$3.00K 10-Q · filed 2023-11-09 | $5.00K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $8.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $199.00K 10-K · filed 2024-03-06 | |||
| 2021-09-30 | $1.00K 10-Q · filed 2022-11-09 | $141.00K derived: sum of 2 quarters · filed 2022-11-09 | $173.00K derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $140.00K 10-Q · filed 2022-11-09 | $172.00K derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $32.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $172.00K 10-K · filed 2022-03-11 | |||
| 2020-06-30 | $72.00K 10-Q · filed 2021-11-10 | $82.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $10.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |